GlobalData : Despite positive efficacy data highlighted at AAN 2024, Axsome Therapeutic’s ASX-07 will struggle to make significant impact in acute migraine market, says GlobalData
April 19, 2024 at 12:08 am EDT
Share
18 Apr, 2024 Despite positive efficacy data highlighted at AAN 2024, Axsome Therapeutic's ASX-07 will struggle to make significant impact in acute migraine market, says GlobalData
Following a poster presentation at the American Academy of Neurology (AAN) 2024 annual meeting of new pooled data from two Phase III trials, MOMENTUM (NCT0389600) and INTRCEPT (NCT04163185), evaluatingAxsome Therapeutics's AXS-07 (MoSEIC™ meloxicam and rizatriptan) as a novel acute combination treatment for migraine;
Philippa Salter, SeniorNeurology Analyst atGlobalData, a leading data and analytics company, offers her view:
"Although the migraine market is saturated with acute treatments, the key opinion leaders (KOLs) interviewed by GlobalData welcomed the combination product as an alternative acute treatment option, pointing out that the combination was more effective that rizatriptan monotherapy in clinical trials.
"However, other KOLs had reservations about the combination product preferring monotherapy in their migraine treatment strategy. Some KOLs also raised concerns around the potential high cost of AXS-07 in a market where there are multiple triptan therapies with wide cheap, generic availability, including rizatriptan.
"Further, some KOLs likened AXS-07 to Currax Pharmaceuticals's Treximet, a combination tablet containing sumatriptan and naproxen which, despite being the first and only approved combination prescription medicine for migraine treatment, has seen its uptake hindered by its cost (five times the cost of taking a tablet of generic sumatriptan and a tablet of naproxen in the US) since its launch in 2008.
"Axsome Therapeutics is expecting to resubmit a new drug application (NDA) for ASX-07 in H2 2024 following a complete response letter received from the FDA in May 2022. However, due to the significant competition in the acute migraine market, not only from generic triptans but also from the new class of gepants, with AbbVie's Ubrelvy (ubrogepant), and Pzifer's Nurtec (Rimegepant) and Zavzpret (zavegepant) all approved in the US for acute migraine treatment, it is unlikely that AXS-07 will have a large impact in the migraine market."
Media Enquiries
If you are a member of the press or media and require any further information, please get in touch, as we're very happy to help.
GlobalData plc published this content on
18 April 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
19 April 2024 04:07:03 UTC.
GlobalData Plc is a United Kingdom-based intelligence provider. The Company's principal activity is to provide business information in the form of proprietary data, analytics, and insights to clients in multiple sectors. The Company maintains a centralized operating model and single product platform (One Platform), which is underpinned by a common taxonomy, shared development resource, and new data science technologies. The Company offers Intelligence Centers, which includes market intelligence and thematic intelligence; Consultancy, which provides custom solutions, and Marketplace, which includes report store, company profiles, direct data services, newsletters and free intelligence. It serves corporates, financial institutions, professional services and others. It covers various industries, including aerospace, defense and security, agribusiness, apparel, automotive, banking and payments, construction, consumer, foodservice, healthcare, insurance, medical devices, and mining.
GlobalData : Despite positive efficacy data highlighted at AAN 2024, Axsome Therapeutic’s ASX-07 will struggle to make significant impact in acute migraine market, says GlobalData